Three big-yielding dividend stocks I’d happily buy and hold for 5, 10 and 25 years

Royston Wild looks at three splendid income shares that he thinks could make you a mint in the years ahead.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Unite Group (LSE: UTG) is a share that I’d be content to hold for the next five years as the stream of students to British universities flows on and on.

The student accommodation provider continues to thrive because of solid ‘digs’ demand from both domestic and foreign students. This was shown in trading commentary last month in which chief financial officer Joe Lister declared that “bookings for the 2019/20 academic year have started strongly with 67% of rooms already sold, with 57% guaranteed by nominations agreements at rental levels that are supportive of delivering rental growth in line with our target of 3.0-3.5%.”

The implications of Brexit on broader immigration is uncertain. But I’m not expecting it to have a devastating effect on student numbers from abroad, at least not in the short- to-medium-term. I think the FTSE 250 firm should still deliver strong shareholder returns for a little while longer at least. And a 3.7% forward dividend yield makes it look mighty attractive, too.

I own this!

So great is Britain’s need to build houses that I’d be happy to cling onto Ibstock (LSE: IBST) — a stock that I grabbed a slice of in the spring of 2017 — for at least another 10 years. I was tempted in by its big dividends and, as I type, the prospective yield stands at a titanic 6.1%.

Just how ineffective government housing policy has been to meet the accommodation of a growing population is no secret. Report after report reveals the scale of the problem and has led to the current Tory administration to pledge 300,000 new homes to be built per year by the middle of the next decade.

Ibstock’s bricks, then, look set to remain in strong demand. A mix of price improvements and rising volumes helped revenues rise 8% in 2018. And the opening of its Leicestershire mega-factory last July, a move that doubled production capacity, will put it in great shape to keep growing sales in the years ahead.

A Footsie favourite

GlaxoSmithKline (LSE: GSK) is another share I’d be happy to hold tightly onto for many years in the future. Indeed, given its position at the coalface of pharmaceutical innovation, it’s a share I can see delivering exceptional shareholder returns over the next 25 years, at least.

Medical care is one of things that we can simply not do without, obviously. Good health for us and our loved ones is the number-one priority, meaning that GlaxoSmithKline’s products keep flying off chemists’ shelves, irrespective of broader economic turmoil in certain regions. In fact, the FTSE 100 company’s global sales outlook is getting better and better as wealth levels in emerging markets rise.

The drugs giant saw constant-currency sales to developing regions rise 4% in 2018, it announced this week. I’m expecting its sales performance to pick up, too, following new chief executive Emma Walmsley’s vow to shake up GlaxoSmithKline’s strategy in exciting growth regions, such as Africa. I feel it’s a great blue-chip to pick up today, its appeal boosted by a giant forward dividend yield of 5.1%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild owns shares of Ibstock. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

The Rolls-Royce share price hit new highs in November. What next?

November has been another record-breaking month for the Rolls-Royce share price. And the outlook for 2025 still looks bright.

Read more »

Investing Articles

Here’s the growth forecast for Sage Group shares to 2026!

Sage Group shares have rocketed following the tech firm's stunning third-quarter update. Is now the time to consider buying in?

Read more »

Investing Articles

10%+ dividend growth! 2 FTSE 250 shares tipped to turbocharge dividends

These FTSE 250 income shares look in great shape to grow their dividends by double-digit percentages, says our writer Royston…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

Would it be madness to buy this FTSE stock smashed by Donald Trump’s team picks?

Ben McPoland takes a look at one FTSE share inside his portfolio that has been battered lately due to a…

Read more »

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »